MAP3K1 and cancer: The most prominent cancer-related mutations in our cohort occurred in TP53 (49.9%), PIK3CA (30.1%), GATA3 (10.0%), NF1 (6.0%), and MAP3K1 (5.4%) (Fig. 2a, b).